PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 27 PubMed articles · model: gemma4:31b
Summary
Background
Active compounds
Mechanism of action
Clinical evidence
Pooled analysis of RCTs showed a significant improvement in sperm motility and forward motility, though no significant impact on sperm count or morphology [PMID:32271472].
Coenzyme Q10 is associated with low adverse events and has Level C evidence for the prevention of migraines [PMID:39853578].
Efficacy appears most promising for these conditions, with CoQ10 gaining orphan drug status for certain encephalomyopathies [PMID:16190504].
Systematic review suggests sparse but promising findings as an adjunct in prevention and treatment, though some data indicate a null effect [PMID:28481148].
Supplementation may lower lipid peroxidation and reduce muscle damage indicators such as creatine kinase, lactate dehydrogenase, and myoglobin [PMID:40411469].
Safety & adverse effects
Drug interactions
Evidence summary
PubMed sources
- 1.PMID: 32933108 (2020) — Disorders of Human Coenzyme Q10 Metabolism: An Overview. · International journal of molecular sciences
- 2.PMID: 38718156 (2012) — Coenzyme Q10 and Autoimmune Disorders: An Overview. · International journal of molecular sciences
- 3.PMID: 39853578 (2025) — Nutraceuticals and Headache 2024: Riboflavin, Coenzyme Q10, Feverfew, Magnesium, Melatonin, and Butterbur. · Current pain and headache reports
- 4.PMID: 16190504 (2005) — Coenzyme Q10. · American family physician
- 5.PMID: 25126052 (2014) — Coenzyme q10 therapy. · Molecular syndromology